---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-186747"
form_type: "8-K"
ticker: "NAMS"
cik: "0001936258"
company_name: "NewAmsterdam Pharma Co N.V."
filed_at: "2024-07-29T23:59:59+00:00"
generated_at: "2026-05-31T15:48:13.278053+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# NAMS: Phase 3 BROOKLYN trial of obicetrapib meets primary endpoint; LDL-C down 36.3% at day 84

## Summary
- LDL-C reduced 36.3% vs placebo at day 84 and 41.5% at day 365, both p<0.0001.
- 51% of patients on obicetrapib achieved LDL-C below 70 mg/dL.
- Safety comparable to placebo; TEAEs 63.7% vs 70.3%, discontinuation 7.6% vs 14.4%.
- Mean baseline LDL-C was 123 mg/dL despite 79% on high-intensity statins.
- Next data readouts: BROADWAY (Q4 2024) and TANDEM (Q1 2025).

## SEC filing metadata
- accession: 0001193125-24-186747
- form_type: 8-K
- ticker: NAMS
- cik: 0001936258
- company_name: NewAmsterdam Pharma Co N.V.
- filed_at: 2024-07-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1936258/000119312524186747/0001193125-24-186747-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1936258/000119312524186747/d660026d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-186747
- JSON: https://secwatch.observer/filing/0001193125-24-186747.json
- Plain text: https://secwatch.observer/filing/0001193125-24-186747.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.